ÐÂÎÅÖÐÐÄ
News Center
bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£¨ÈüÍ×£©»ñÅúÉÏÊÐ
Ðû²¼Ê±¼ä£º2023-07-27
7ÔÂ27ÈÕ£¬£¬ £¬£¬£¬ÓÉbevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾Á¥Êô¹«Ë¾Õý´óÌìÇçÑб¬·¢²úµÄ×¢ÉäÓÃÇúÍ×Öéµ¥¿¹ÉúÎïÀàËÆÒ©£¨ÉÌÆ·Ãû£ºÈüÍ×£©Õýʽ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©Åú׼ǩ·¢µÄ¡¶Ò©Æ·×¢²áÖ¤Êé¡·£¬£¬ £¬£¬£¬Åú×¼ÓÃÓÚHER2ÑôÐÔÔçÆÚÈéÏÙ°©¡¢×ªÒÆÐÔÈéÏÙ°©¼°×ªÒÆÐÔθ°©µÄÖÎÁÆ¡£¡£¡£¡£¡£
ÈüÍ×£¨×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£©µÄ»ñÅú»ùÓÚÒ»ÏîTQ-B211ÍŽá¶àÎ÷ËûÈüÓëºÕÈüÍ¡ÍŽá¶àÎ÷ËûÈüÒ»ÏßÖÎÁÆ HER2 ÑôÐÔתÒÆÐÔÈéÏÙ°©»¼ÕßµÄÓÐÓÃÐÔ¡¢Çå¾²ÐÔºÍÃâÒßÔÐÔµÄ˫ä¡¢Ëæ»ú»¯¡¢¶àÖÐÐÄ¡¢III ÆÚÁÙ´²Ñо¿¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬ £¬£¬£¬Æ¾Ö¤ÒâÏòÖÎÁÆÆÊÎöÈËȺ£¨ITT£©»òÇкϼƻ®¼¯£¨PPS£©ÆÊÎö£¬£¬ £¬£¬£¬TQ-B211 ×éÓëºÕÈüÍ¡±ÈÕÕ×éÁ½×é¼ä×ÔÁ¦Ó°ÏñÆÀ¹ÀÈ·È쵀 24 ÖÜ£¨8 ¸öÖÜÆÚ£©ÄڵĿ͹ۻº½âÂÊ£¨ORR24w£©RR ÖµµÄ90%CI ÂäÔÚµÈЧÐÔ½çÖµ£¨0.80£¬£¬ £¬£¬£¬1.25£©ÄÚ£¬£¬ £¬£¬£¬Ö¤ÊµÁ½×éÒ©ÎïµÈЧ¡£¡£¡£¡£¡£×ÔÁ¦Ó°ÏñÆÀ¹ÀµÄ24ÖÜÄÚ¼²²¡¿ØÖÆÂÊ£¨DCR£©»ººÍ½âÒ»Á¬Ê±¼ä£¨DOR£©¡¢×ÔÁ¦Ó°ÏñÆÀ¹ÀÍŽáÖÎÁÆʱ´úµÄÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©ÒÔ¼°×ÜÉúÑÄÆڵȴÎÒªÖ¸±ê£¬£¬ £¬£¬£¬Á½×é¼ä²î±ð¾ùÎÞͳ¼ÆѧÒâÒå¡£¡£¡£¡£¡£Çå¾²ÐÔ·½Ã棬£¬ £¬£¬£¬TQ-B211×éºÍºÕÈüÍ¡Á½×é¼ä AE ºÍ 3 ¼¶¼°ÒÔÉÏ AE ±¬·¢ÂÊÏà½ü£¬£¬ £¬£¬£¬Ö¤ÊµÁ½ÕßÇå¾²ÐÔÏàËƹ¡£¡£¡£¡£¡£
ÈüÍ×£¨×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£©ÑÏ¿á×ñÕÕÖйúÉúÎïÀàËÆÒ©Ñз¢ÓëÆÀ¼ÛÊÖÒÕÖ¸µ¼ÔÔòÑÐÖÆ¡£¡£¡£¡£¡£Æä¹æ¸ñΪ150mg/Æ¿£¬£¬ £¬£¬£¬¼´Åä¼´Ó㬣¬ £¬£¬£¬ÎÞÐè¾ÙÐÐÓàÒºÉúÑÄ£¬£¬ £¬£¬£¬¼È½µµÍÁËÁÙ´²Ò½»¤Ö°Ô±µÄÊÂÇéÁ¿£¬£¬ £¬£¬£¬Ò²×èÖ¹ÒòÒ©Æ·ÉúÑIJ»µ±¶ø´øÀ´µÄΣº¦¡£¡£¡£¡£¡£Í¬Ê±£¬£¬ £¬£¬£¬Ð¡¹æ¸ñ¼ÁÁ¿°ü×°ÎÞÐèÌí¼Ó±½¼×´¼×÷Ϊ·À¸¯¼ÁÀ´°ü¹ÜÒ©ÎïÎȹÌÐÔ£¬£¬ £¬£¬£¬½µµÍÁÙ´²ÖÎÁÆÀú³ÌÖÐÒòÒ©ÎïÂѰ׽ṹ¸Ä±äµ¼ÖÂÖÎÁÆЧ¹û²»¼ÑµÄΣº¦£¬£¬ £¬£¬£¬×ÊÖú»¼ÕßïÔ̱¬·¢ÈÜѪ×÷Óá¢Í·ÔΡ¢Í·Í´¡¢¶ñÐÄÍÂÄæµÈ²»Á¼·´Ó¦²£¬£¬ £¬£¬£¬ÊµÏÖ»¼Õߺã¾Ã¸ßÖÊÁ¿ÉúÑÄ£¬£¬ £¬£¬£¬»Ý¼°¸ü¶à»¼ÕߺͼÒÍ¥¡£¡£¡£¡£¡£
ÈéÏÙ°©ÊÇÍþвȫÇòÅ®ÐÔ¿µ½¡µÄµÚÒ»´ó¶ñÐÔÖ×Áö£¬£¬ £¬£¬£¬2020ÄêÖйúÈ·ÕïÈéÏÙ°©²¡Àý¿¿½ü42Íò¡£¡£¡£¡£¡£ÆäÖУ¬£¬ £¬£¬£¬HER2ÑôÐÔÈéÏÙ°©Ô¼Õ¼ËùÓÐÈéÏÙ°©²¡ÀýµÄ15%-20%£¬£¬ £¬£¬£¬Ö×Áöϸ°û¶ñÐÔˮƽ¸ü¸ß¡¢¼²²¡Ï£Íû¸ü¿ì£¬£¬ £¬£¬£¬Í¬Ê±¸üÒ×±¬·¢×ªÒƺ͸´·¢³¡£¡£¡£¡£¡£ÈüÍ×£¨×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£©µÄ»ñÅúÉÏÊУ¬£¬ £¬£¬£¬ÎªHER2ÑôÐÔÈéÏÙ°©ºÍθ°©»¼ÕßÌṩÁËеÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£
ÔÚÈéÏÙ°©µÈ¾ßÓнϴóÁÙ´²ÐèÇóµÄÖÎÁÆÁìÓòÉÏ£¬£¬ £¬£¬£¬Õý´óÌìÇç×ÅÑÛÓÚδÀ´£¬£¬ £¬£¬£¬Æð¾¢Õö¿ªÆÕ±éµÄ½á¹¹¡£¡£¡£¡£¡£Õë¶ÔHER2ÑôÐÔÈéÏÙ°©»¼Õߣ¬£¬ £¬£¬£¬³ýÁËÀÖ³ÉÍƳöÇúÍ×Öéµ¥¿¹£¬£¬ £¬£¬£¬¹«Ë¾ºóÐø»¹½«ÍƳöÅÁÍ×Öéµ¥¿¹ÉúÎïÀàËÆÒ©£¬£¬ £¬£¬£¬ÐγɓÇúÅÁ×éºÏ”¡£¡£¡£¡£¡£±ðµÄ£¬£¬ £¬£¬£¬¹«Ë¾Ò»Á¬Ñз¢¶à¿îÐÂÒ©£¬£¬ £¬£¬£¬ÆäÖаüÀ¨Ë«¿¹ºÍË«¿¹ADCÒ©ÎïµÈ£¬£¬ £¬£¬£¬½øÒ»²½½«ÖÎÁÆÈËȺÍØÕ¹ÖÁHER2µÍ±í´ïÈËȺ£¬£¬ £¬£¬£¬Îª°©Ö¢»¼ÕßÌṩ¸ü¶à¸üÓÅÖʵÄÖÎÁÆÑ¡Ôñ£¬£¬ £¬£¬£¬Îª¿í´ó»¼Õß´øÀ´¸ü¶àÏ£Íû¡£¡£¡£¡£¡£
²Î¿¼×ÊÁÏ£º
1.ÈüÍ×ÄÚ²¿×ÊÁÏ¡£¡£¡£¡£¡£¸ÃIIIÆÚÁÙ´²Êý¾ÝΪNMPAÉóÅúͨ¹ý²¢Ö§³Ö²úÆ·ÉÏÊеÄÁÙ´²Êý¾Ý£¨ÔÝδ¹ûÕ棩;
2.Le Basle Y, et al. J Pharm Sci 2020;109(1)£º169-190;
3.Gion M,Trapani D,Cortés A,et al.Systemic Therapy for HER2-Positive Metastatic Breast Cancer:Moving Into a New Era.Am Soc Clin Oncol Educ Book.2022 Apr;42:1-11.